Skip to main content
Clinical Trials/NCT06043505
NCT06043505
Recruiting
Not Applicable

Impact of an Echographic Algorithm on Hemodynamic Optimization in the First 4 Days of Septic Shock Management: a Multicentric, Randomized, Controlled, Open Label Pilot-study

Centre Hospitalier Universitaire de Nīmes1 site in 1 country136 target enrollmentFebruary 8, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Shock, Septic
Sponsor
Centre Hospitalier Universitaire de Nīmes
Enrollment
136
Locations
1
Primary Endpoint
Volume of vascular filling during the first 4 days
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Fluid management is one of the key issues in the initial management of septic shock (SS). Fluid overload and hypovolemia have been associated with increased mortality in several trials. Transthoracic echocardiography (TTE) and lung ultrasound are recommended for haemodynamic assessment in critically ill patients. However, the benefit of hemodynamic optimisation using echography has not been yet evaluated. The purpose of this multicenter, controlled, randomized trial is to assess the impact of an echocardiographic algorithm of hemodynamic optimization on fluid management in septic patients during the first 4 days of therapy.

Registry
clinicaltrials.gov
Start Date
February 8, 2024
End Date
October 26, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Centre Hospitalier Universitaire de Nīmes
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Refusal of consent.
  • Patient under court protection or guardianship.
  • Moribund patient with a life expectancy of less than 48 hours.
  • Non-echogenic patient.
  • Cardiac tamponade.
  • Infective endocarditis.
  • Intracavitary thrombus.
  • Dilated cardiomyopathy with LVEF (Left Ventricular Ejection Fraction\<40%.
  • Parturient or nursing patient.

Outcomes

Primary Outcomes

Volume of vascular filling during the first 4 days

Time Frame: Day 4

This takes into account the cumulative volume of vascular filling administered to improve cardiac output during the 4 first days, measured in Liter (L)

Secondary Outcomes

  • Analysis of the primary endpoint related to severe renal dysfunction(Day 4)
  • .Analysis of the primary endpoint related to ARDS ([acute respiratory distress syndrome, according to Berlin criteria)(Day 4)
  • Analysis of the primary endpoint in relation with patient severity(Day 4)
  • Mortality(Day 28)
  • Time to normalization of lactatemia (<2 mmol/l)(Day 4)
  • Number of days alive without failure at Day 28(Day 28)
  • Therapeutic adjustments including bolus vascular filling, changes in vasopressor flow, and administration of diuretics(Day 4)
  • Adverse effects(Day 28)
  • Fluid balance in L(Day 4)
  • Length of stay in ICU (ready for discharge)(Day 28)
  • Length of stay in hospital(Day 28)

Study Sites (1)

Loading locations...

Similar Trials